Agents that target the TH17-interleukin pathway show promise in psoriatic arthritis, as alternatives for patients who don't benefit from TNFα blockers. This slide show describes their mode of action and potential.
Psoriasis Associated with Being Overweight, Obesity, Study Finds
Emerging Agents in the Treatment of Rheumatic Diseases
Smartphone Notifications Helps Prevent Missed Doses for Gout Medication
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
Treating Gout Flares with Opioid Therapy Links to Chronic Opioid Use
Acute Calcium Pyrophosphate Deposition Arthritis Shown to Doubles Patients’ Risk of Fracture